 | Biotech Buzz: Axovant Sciences Ltd, Summit Therapeutics PLC (ADR), and Mylan NV (LON:SUMM)
www.schaeffersresearch.com - September 26 at 7:33 PM |
 | FTSE 100 slumps 80 points as it waits on US presidential debate (LON:SUMM)
www.proactiveinvestors.co.uk - September 26 at 11:57 AM |
 | Mid-Morning Market Update: Markets Open Lower; Cal-Maine Posts Wider-Than-Expected Loss (LON:SUMM)
www.nasdaq.com - September 26 at 11:57 AM |
 | Summit Therapeutics Plc :SUMM-GB: Earnings Analysis: Q2, 2017 By the Numbers : September 15, 2016 (LON:SUMM)
www.capitalcube.com - September 15 at 11:11 AM |
 | Summit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy Community (LON:SUMM)
www.publicnow.com - September 12 at 11:19 AM |
 | Summit Therapeutics plc : Half-yearly report (LON:SUMM)
inpublic.globenewswire.com - September 9 at 11:19 AM |
 | Summit Therapeutics highlights clinical progress (LON:SUMM)
www.proactiveinvestors.com - September 9 at 11:19 AM |
 | Summit Therapeutics to Report Financial Results for the Second Quarter Ended 31 July 2016 on 8 September 2016 (LON:SUMM)
finance.yahoo.com - September 5 at 11:23 AM |
 | Summit Therapeutics Sees Positive Phase I Trial Results For Ezutromid (LON:SUMM)
www.morningstar.co.uk - August 9 at 10:56 AM |
 | Summit Therapeutics : Shows Further Positive Trial Data For Ridinilazole (LON:SUMM)
www.4-traders.com - June 22 at 10:58 AM |
| Summit uses more than gut instinct to prove C.diff antibiotic's worth (LON:SUMM)
www.proactiveinvestors.com - June 22 at 10:58 AM |
| First Quarter Financial Results (LON:SUMM)
www.publicnow.com - June 21 at 12:09 PM |
| Summit Therapeutics : Enrols First Patient In Phase II Ezutromid Trial (LON:SUMM)
www.4-traders.com - June 17 at 10:18 AM |
| Summit Therapeutics recruits first phase II DMD patient (LON:SUMM)
www.proactiveinvestors.com - June 17 at 10:18 AM |
 | 5 Attractive Biotechnology Stocks For Healthy, Long-Term Returns (LON:SUMM)
seekingalpha.com - June 10 at 7:59 PM |
 | Duchenne Muscular Dystrophy Global Clinical Trials Review, H1, 2016 - New Market Research Report (LON:SUMM)
www.sbwire.com - June 10 at 7:59 PM |
| Q1 2017 Summit Therapeutics PLC Earnings Release - Time Not Supplied (LON:SUMM)
biz.yahoo.com - June 2 at 7:07 AM |
 | Caldan Therapeutics bolsters senior team (LON:SUMM)
www.pmlive.com - May 31 at 8:02 PM |
 | Summit Therapeutics plc ( SUMM ) (LON:SUMM)
www.iii.co.uk - February 26 at 1:32 PM |
| Summit Therapeutics Announces Publication of Preclinical Data Showing Ridinilazole Outperformed Standard of Care in Reducing C. Difficile Toxins That Drive Disease Symptoms (LON:SUMM)
finance.yahoo.com - February 24 at 7:00 AM |
| Will Edwards thought nothing of his own safety when he saw flames engulfing the car when it burst into flames on the M60 (LON:SUMM)
www.ad-hoc-news.de - February 5 at 3:00 PM |
| Summit Therapeutics to Present at 18th Annual BIO CEO & Investor Conference (LON:SUMM)
finance.yahoo.com - February 3 at 7:00 AM |
| Recent Broker Updates On Summit Therapeutics Plc (SMMT) - Risers & Fallers (LON:SUMM)
www.risersandfallers.com - January 29 at 2:17 PM |
| Recent Broker Updates On Summit Therapeutics (LON:SUMM) - Risers & Fallers (LON:SUMM)
www.risersandfallers.com - January 28 at 2:11 PM |
| Oppenheimer Thinks Summit Therapeutics' Stock is Going to Recover - Analyst Ratings (LON:SUMM)
www.analystratings.com - January 26 at 2:15 PM |
| Summit Therapeutics gets European patent for antibiotic ridinilazole to treat C. difficile infection - pharmabiz.com (LON:SUMM)
www.pharmabiz.com - January 22 at 8:15 PM |
| Summit Therapeutics gets European patent for antibiotic ridinilazole to treat C. difficile infection (LON:SUMM)
pharmabiz.com - January 22 at 1:13 PM |
 | Peptide Therapeutics Market Will Rise at a Moderate 2.8% CAGR to Touch US$23.7 ... - SYS-CON Media (press release) (LON:SUMM)
news.sys-con.com - January 21 at 1:26 PM |
 | Summit Therapeutics Gets UK OK to Start Phase 2 Trial of Duchenne Muscular ... - WallStreet.org (LON:SUMM)
www.wallstreet.org - January 21 at 1:26 PM |
 | Ayretrade, Inc. (SUMM) Granted Key European Patent for Ridinilazole for Treatment of C. Difficile (LON:SUMM)
www.streetinsider.com - January 21 at 1:26 PM |
 | Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial in DMD (LON:SUMM)
www.finanznachrichten.de - January 21 at 1:26 PM |
 | Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD (LON:SUMM)
www.noodls.com - January 21 at 7:25 AM |
| Summit Therapeutics Granted Key European Patent - ag-IP-news Agency (LON:SUMM)
www.ag-ip-news.com - January 20 at 1:11 PM |
| Summit Therapeutics Granted Key European Patent for Novel Antibiotic Ridinilazole for Treatment of C. Difficile ... - GlobeNewswire (press release) (LON:SUMM)
globenewswire.com - January 19 at 7:53 PM |
 | Summit Therapeutics Granted Key European Patent for Novel Antibiotic ... - CNNMoney (LON:SUMM)
money.cnn.com - January 19 at 12:46 PM |
| Price Target Update On Summit Therapeutics Plc (SMMT) - Risers & Fallers (LON:SUMM)
www.risersandfallers.com - January 19 at 12:46 PM |
| Grant of Key European Patent for Novel Antibiotic Ridinilazole for Treatment of CDI (LON:SUMM)
www.noodls.com - January 19 at 7:15 AM |
| Summit Therapeutics Granted Key European Patent for Novel Antibiotic Ridinilazole for Treatment of C. Difficile Infection (LON:SUMM)
finance.yahoo.com - January 19 at 7:00 AM |
| Summit Therapeutics Plc breached its 50 day moving average in a Bearish Manner : January 14, 2016 (LON:SUMM)
www.capitalcube.com - January 14 at 4:34 AM |
| Q3 2016 Summit Therapeutics PLC Earnings Release - Time Not Supplied (LON:SUMM)
biz.yahoo.com - December 17 at 7:07 AM |
